Medifast (NYSE:MED) Releases Q4 2025 Earnings Guidance

Medifast (NYSE:MED) updated its fourth quarter 2025 earnings guidance on Monday. The company provided earnings per share (EPS) guidance of -1.250–0.70 for the period, compared to the consensus estimate of -0.230. The company issued revenue guidance of $65.0 million-$80.0 million, compared to the consensus revenue estimate of $85.1 million.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (d)” rating on shares of Medifast in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Medifast has a consensus rating of “Reduce” and an average price target of $16.50.

Medifast Price Performance

Shares of NYSE:MED opened at $11.76 on Tuesday. The firm has a 50 day simple moving average of $13.52 and a 200 day simple moving average of $13.54. The company has a market cap of $129.24 million, a price-to-earnings ratio of 36.75 and a beta of 0.85. Medifast has a one year low of $11.25 and a one year high of $21.98.

Medifast (NYSE:MED) last released its quarterly earnings results on Monday, November 3rd. The specialty retailer reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.20). The business had revenue of $89.41 million for the quarter, compared to the consensus estimate of $84.10 million. Medifast had a net margin of 0.76% and a return on equity of 2.00%. Medifast has set its Q4 2025 guidance at -1.250–0.70 EPS. As a group, analysts expect that Medifast will post 0.51 EPS for the current year.

Hedge Funds Weigh In On Medifast

A number of hedge funds have recently bought and sold shares of the company. Man Group plc raised its stake in Medifast by 0.6% during the second quarter. Man Group plc now owns 198,156 shares of the specialty retailer’s stock worth $2,784,000 after buying an additional 1,200 shares during the last quarter. Engineers Gate Manager LP bought a new position in Medifast during the second quarter worth $161,000. Bridgeway Capital Management LLC raised its stake in Medifast by 164.6% during the second quarter. Bridgeway Capital Management LLC now owns 57,944 shares of the specialty retailer’s stock worth $814,000 after buying an additional 36,044 shares during the last quarter. Bank of America Corp DE grew its holdings in Medifast by 37.4% in the second quarter. Bank of America Corp DE now owns 396,369 shares of the specialty retailer’s stock worth $5,569,000 after purchasing an additional 107,854 shares during the period. Finally, Ameriprise Financial Inc. grew its holdings in Medifast by 9.0% in the second quarter. Ameriprise Financial Inc. now owns 76,801 shares of the specialty retailer’s stock worth $1,079,000 after purchasing an additional 6,322 shares during the period. Institutional investors own 95.51% of the company’s stock.

Medifast Company Profile

Medifast, Inc, through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names.